Acylideneoxoindoles: A new class of reversible inhibitors of human transglutaminase 2
摘要:
Inhibitors of human transglutaminase 2 (TG2) are anticipated to be useful in the therapy of a variety of diseases including celiac sprue as well as certain CNS disorders and cancers. A class of 3-acylidene-2-oxoindoles was identified as potent reversible inhibitors of human TG2. Structure-activity relationship analysis of a lead compound led to the generation of several potent, competitive inhibitors. Analogs with significant non-competitive character were also identified, suggesting that the compounds bind at one or more allosteric regulatory sites on this multidomain enzyme. The most active compounds had K(i) values below 1.0 mu M in two different kinetic assays for human TG2, and may therefore be suitable for investigations into the role of TG2 in physiology and disease in animals. (C) 2010 Elsevier Ltd. All rights reserved.
[EN] 3-ACYLIDENE-2-OXOINDOLE DERIVATIVES FOR INHIBITION OF TRANSGLUTAMINASE 2<br/>[FR] DÉRIVÉS 3-ACYLIDÈNE-2-OXOINDOLE DESTINÉS À INHIBER LA TRANSGLUTAMINASE 2
申请人:NUMERATE INC
公开号:WO2012078519A2
公开(公告)日:2012-06-14
Provided herein are acylidene oxoindole derivatives, compositions including them, and methods of inhibiting transglutaminase 2 and treating diseases mediated by transglutaminase 2 by administering such derivatives and compositions.
Acylideneoxoindoles: A new class of reversible inhibitors of human transglutaminase 2
作者:Cornelius Klöck、Xi Jin、Kihang Choi、Chaitan Khosla、Peter B. Madrid、Andrew Spencer、Brian C. Raimundo、Paul Boardman、Guido Lanza、John H. Griffin
DOI:10.1016/j.bmcl.2010.12.037
日期:2011.5
Inhibitors of human transglutaminase 2 (TG2) are anticipated to be useful in the therapy of a variety of diseases including celiac sprue as well as certain CNS disorders and cancers. A class of 3-acylidene-2-oxoindoles was identified as potent reversible inhibitors of human TG2. Structure-activity relationship analysis of a lead compound led to the generation of several potent, competitive inhibitors. Analogs with significant non-competitive character were also identified, suggesting that the compounds bind at one or more allosteric regulatory sites on this multidomain enzyme. The most active compounds had K(i) values below 1.0 mu M in two different kinetic assays for human TG2, and may therefore be suitable for investigations into the role of TG2 in physiology and disease in animals. (C) 2010 Elsevier Ltd. All rights reserved.